BU-NOT-SET
- New brand strategy highlights Recipharm's end-to-end capabilities and provides a clear structure across oral dosage, sterile delivery and advanced therapies.
- Recipharm Advanced Bio, formerly known as ReciBioPharm, strengthens alignment with the Recipharm master brand.
- One brand, one partner, one Recipharm.
Recipharm, a leading global contract development and manufacturing organisation (CDMO), today unveiled a refreshed brand strategy that showcases the breadth and depth of its capabilities, and reinforces the company's ongoing commitment to delivering quality, reliability and value for its customers worldwide.
As the demands of pharmaceutical and biotech companies evolve, Recipharm's updated brand strategy provides customers with clear view of its full offering, helping them engage seamlessly with the right expertise at every stage of the development and manufacturing journey.
Recipharm's offerings spans three core areas: oral dosage, sterile delivery and advanced bio. As part of this update, the advanced therapies division, formerly known as ReciBioPharm, now operates under the name Recipharm Advanced Bio, strengthening its connection with the master brand. Oral dosage and sterile delivery remain long-established parts of Recipharm's business, continuing to deliver value while benefiting from and contributing to, the reputation and strength of the Recipharm name.
Greg Behar, CEO at Recipharm, said: "Recipharm has built its reputation on expertise, scale and dependable performance to deliver consistently, on time and with quality. This brand evolution is about expressing those strengths in a way that reflects the full scope of what we do, and makes it even more straight forward for customers to engage with us. It reinforces the trust that partners already place in the Recipharm name and demonstrate our commitment to supporting their success across every stage of the journey."
In addition, to further enhance customer experience, Recipharm has introduced a range of branded tools and solutions:
- The ReciPredict™ modelling plaform: AI-driven simulation and modelling platform to reduce and de-risk tech transfer timelines and costs;
- The ReciDev™ offerings: product development support providing scalable solutions and expertise;
- The Recimagine™ platform: an advanced, inline analytical ecosystem that provides real-time QC insights, simulated process development and enables continuous manufacturing of advanced therapies;
- The ReciCore™ suite of solutions: AI and digital solutions designed to optimise project execution and quality and compliance.
This brand evolution is a reflection of what Recipharm has always been known for: deep expertise, broad capabilities, dependable performance and the trust of its partners.
Whether customers are bringing a new therapy to market or scaling an established product, Recipharm offers clear, specialised support, without compromising on quality, timelines or reliability.
Ends)
For more information
About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) employing over 5,000 employees worldwide. Recipharm provides manufacturing services of pharmaceuticals in various dosage forms, including sterile fill & finish, oral solid dosage and biologics; clinical trial material development and manufacturing services; and pharmaceutical product development. Its Recipharm Advanced Bio segment works with customers to develop and commercialise advanced therapy medicinal products (ATMPs): pre-clinical to clinical development, commercial development and manufacture for new biological modalities, encompassing technologies based on live viruses and viral vectors, live-microbial biopharmaceutical products, nucleic acid-based mRNA and plasmid DNA production.
Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. It operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden and the US.
For more information on Recipharm, please visit www.recipharm.com
Media contact:
Guenaelle Holloway, Head of communications
[email protected]
+44 7730 303 708